Omega-3 fatty acid deficiency: A preventable risk factor for schizophrenia?

Schizophrenia Research

Volumn 129, Issue 2-3, 2011, Pages 215-216

  McNamara, Robert K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; RISPERIDONE;

ERYTHROCYTE LEVEL; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SUPPLEMENTATION;

DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 79957979702     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2010.12.017     Document Type: Letter

References (13)

1. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
2. Delion S., Chalon S., Guilloteau D., Besnard J.C., Durand G. alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 1996, 66:1582-1591.
3. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:393-399.
4. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 1965, 58:295-300.
5. Horrobin D.F. The effects of antipsychotic drugs on membrane phospholipids: a possible novel mechanism of action of clozapine. Phospholipid Spectrum Disorders in Psychiatry and Neurology 2003, 271-276. Marius Press, Lancashire, UK. 2nd Edition. M. Peet, I. Glen, D.F. Horrobin (Eds.).
6. Jakobik V., Burus I., Decsi T. Fatty acid composition of erythrocyte membrane lipids in healthy subjects from birth to young adulthood. Eur. J. Pediatr. 2009, 168:141-147.
7. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30:901-911.
8. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
9. McNamara R.K., Carlson S.E. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:329-349.
10. McNamara R.K. Evidence-based evaluation of omega-3 fatty acid deficiency as a risk factor for recurrent neuropsychiatric illness: current status and future directions. Fish Oils and Health 2008, 7-67. Nova Science Publishers, Inc, U.S.A. E.P. Heikkinen (Ed.).
11. McNamara R.K. Modulation of polyunsaturated fatty acid biosynthesis by antipsychotic medications: implications for the pathophysiology and treatment of schizophrenia. Clin. Lipidol. 2009, 4:809-820.
12. McNamara R.K., Able J.A., Jandacek R., Rider T., Tso P. Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis. Schizophr. Res. 2009, 107:150-157.
13. Yao J.K., Magan S., Sonel A.F., Gurklis J.A., Sanders R., Reddy R.D. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2004, 71:171-176.